PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33830459-6	2021	Cabotegravir is mainly metabolized by UGT1A1, and rilpivirine is mainly metabolized by CYP3A4, therefore these agents are susceptible to DDIs with inhibitors, and particularly inducers of drug-metabolizing enzymes.	didanosine	137-141	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93
2549385-0	1989	Phosphorylation of 2",3"-dideoxyinosine by cytosolic 5"-nucleotidase of human lymphoid cells.	didanosine	19-39	5'-nucleotidase ecto	Homo sapiens	53-68
3499445-3	1987	Deamination of DDA to 2",3"-dideoxyinosine (DDI) in plasma by adenosine deaminase was monitored by HPLC, and the identification of DDI verified by thermospray HPLC-mass spectrometry.	didanosine	22-42	adenosine deaminase	Homo sapiens	62-81
3499445-3	1987	Deamination of DDA to 2",3"-dideoxyinosine (DDI) in plasma by adenosine deaminase was monitored by HPLC, and the identification of DDI verified by thermospray HPLC-mass spectrometry.	didanosine	44-47	adenosine deaminase	Homo sapiens	62-81
33996073-11	2021	Conclusion: As the online database and apps are free to use, we hope that widespread acceptance and usage will reduce medical misadventure and iatrogenic harm from unconsidered DDIs.	didanosine	177-181	cathepsin B	Homo sapiens	39-43
3262616-3	1988	The metabolism of ddAdo in the kinase-deficient mutants was found to be unchanged by comparison with that in parental cells; however, the inhibition of ddAdo deamination to 2",3"-dideoxyinosine (ddIno) by the adenosine deaminase inhibitor, 2"-deoxycoformycin, reduced ddAdo nucleotide formation in deoxycytidine kinase-deficient, adenosine kinase-deficient, and doubly kinase-deficient mutants by 42, 54, and 80%, respectively.	didanosine	173-193	deoxycytidine kinase	Homo sapiens	298-318
3262616-3	1988	The metabolism of ddAdo in the kinase-deficient mutants was found to be unchanged by comparison with that in parental cells; however, the inhibition of ddAdo deamination to 2",3"-dideoxyinosine (ddIno) by the adenosine deaminase inhibitor, 2"-deoxycoformycin, reduced ddAdo nucleotide formation in deoxycytidine kinase-deficient, adenosine kinase-deficient, and doubly kinase-deficient mutants by 42, 54, and 80%, respectively.	didanosine	195-200	deoxycytidine kinase	Homo sapiens	298-318
32710514-11	2021	Among children misdiagnosed with T1DM, a low DDI requirement was found more frequently in MODY2, whereas beta-cell antibody negativity was more common in MODY1.	didanosine	45-48	glucokinase	Homo sapiens	90-95
33260705-9	2020	CYP2C19/3A4 mediated DDIs and DDGIs showed trends towards increased risks of switching and/or dose reduction.	didanosine	21-25	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
33276942-8	2020	Consequently, in the presence of potential DDIs through CYP3A4, and/or P-gp, LMWHs remain the first-line anticoagulant of choice for the long-term treatment of CAT.	didanosine	43-47	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-62
31397557-10	2019	These results contribute to the evidence that the TGx-DDI biomarker is useful for identifying chemicals that cause DDI and activate p53.	didanosine	54-57	transglutaminase 5	Homo sapiens	50-53
32310900-10	2020	Children exposed to didanosine at conception and during the first trimester had increased risk of neurologic case status (aRR = 2.28, 95% CI 1.07--4.87 and aRR = 2.02, 95% CI 1.01--4.04, respectively), compared with didanosine-unexposed children.	didanosine	20-30	arrestin beta 2	Homo sapiens	122-129
32310900-10	2020	Children exposed to didanosine at conception and during the first trimester had increased risk of neurologic case status (aRR = 2.28, 95% CI 1.07--4.87 and aRR = 2.02, 95% CI 1.01--4.04, respectively), compared with didanosine-unexposed children.	didanosine	20-30	arrestin beta 2	Homo sapiens	156-163
31369085-6	2019	RESULTS: Among the 139 instances of CS identified, 34/35 cases (97%) had DDIs (31 with ritonavir and 3 with cobicistat) and 7/104 controls (7%) had DDIs (6 with itraconazole and 1 with verapamil).	didanosine	73-77	citrate synthase	Homo sapiens	36-38
31653972-3	2019	Treatment of differentiated ARPE-19 or human primary RPE cells with 200 microM ddI for 6-24 days was not cytotoxic but caused up to 60% depletion of mitochondrial DNA, and a similar reduction in mitochondrial membrane potential and NDUFA9 protein abundance.	didanosine	79-82	NADH:ubiquinone oxidoreductase subunit A9	Homo sapiens	232-238
32616542-11	2020	SIGNIFICANCE STATEMENT: Weak CYP3A inhibition and/or induction can sometimes predict DDIs in the intestine but not the liver.	didanosine	85-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-34
32457621-2	2020	We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.	didanosine	118-122	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	53-59
32457621-2	2020	We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.	didanosine	118-122	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	74-80
32457621-2	2020	We aimed to investigate frequency and concordance on CYP2D6, CYP2C19, and CYP2C9 (CYP2D6/2C19/2C9)-mediated potential DDIs at the Lifelines cohort and linked data from the pharmacy database IADB.nl.	didanosine	118-122	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	82-97
30993551-2	2019	The current report investigates another important antiplatelet inhibitor, prasugrel, that is also activated through metabolism by CYP2B6, CYP2C19 and CYP3A4/5, for its CYP-based DDI potential with vonoprazan.	didanosine	178-181	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	130-136
30993551-2	2019	The current report investigates another important antiplatelet inhibitor, prasugrel, that is also activated through metabolism by CYP2B6, CYP2C19 and CYP3A4/5, for its CYP-based DDI potential with vonoprazan.	didanosine	178-181	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	138-145
30993551-2	2019	The current report investigates another important antiplatelet inhibitor, prasugrel, that is also activated through metabolism by CYP2B6, CYP2C19 and CYP3A4/5, for its CYP-based DDI potential with vonoprazan.	didanosine	178-181	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-158
31397557-10	2019	These results contribute to the evidence that the TGx-DDI biomarker is useful for identifying chemicals that cause DDI and activate p53.	didanosine	54-57	tumor protein p53	Homo sapiens	132-135
31397557-10	2019	These results contribute to the evidence that the TGx-DDI biomarker is useful for identifying chemicals that cause DDI and activate p53.	didanosine	115-118	transglutaminase 5	Homo sapiens	50-53
31399063-13	2019	Prior exposure to TA and/or ddI was associated with 9% lower [- 17;-2] plasma adiponectin levels and with excess risk of low adiponectin (aOR 1.74 [1.10; 2.76]).	didanosine	28-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	125-136
31399063-13	2019	Prior exposure to TA and/or ddI was associated with 9% lower [- 17;-2] plasma adiponectin levels and with excess risk of low adiponectin (aOR 1.74 [1.10; 2.76]).	didanosine	28-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	78-89
31399063-14	2019	CONCLUSIONS: We described low adipose tissue density and impaired adiponectin production to be associated with prior exposure to TA and/or ddI even years after treatment discontinuation and independently of adipose tissue area.	didanosine	139-142	adiponectin, C1Q and collagen domain containing	Homo sapiens	66-77
29530865-7	2018	In addition, mutagenic studies identified that 225D and 231L in the N-terminal half of hENT3 partially contribute to the ability of hENT3 to transport AZT and DDI.	didanosine	159-162	solute carrier family 29 member 3	Homo sapiens	87-92
29530865-7	2018	In addition, mutagenic studies identified that 225D and 231L in the N-terminal half of hENT3 partially contribute to the ability of hENT3 to transport AZT and DDI.	didanosine	159-162	solute carrier family 29 member 3	Homo sapiens	132-137
24976398-0	2014	Down-regulation of mitochondrial thymidine kinase 2 and deoxyguanosine kinase by didanosine: implication for mitochondrial toxicities of anti-HIV nucleoside analogs.	didanosine	81-91	thymidine kinase 2	Homo sapiens	33-51
27567380-1	2016	DDI could be caused by the inhibition of OATP-mediated hepatic uptakes.	didanosine	0-3	solute carrier organic anion transporter family member 1A2	Homo sapiens	41-45
27088320-7	2016	Prior exposure to didanosine, longer duration of a CD4 cell count below 500 cells/mul and a lower CD4 cell count at enrollment were each associated with a higher FIB-4.	didanosine	18-28	CD4 molecule	Homo sapiens	98-101
25377427-2	2015	To explore underlying mechanisms, we overexpressed PGC-1alpha, a master regulator of mitochondrial biogenesis, twofold in H9c2 rat cardiomyocyte cultures, hypothesizing that this might protect the mitochondria from damage induced by the NRTI combination zidovudine (AZT) and didanosine (ddI).	didanosine	275-285	PPARG coactivator 1 alpha	Rattus norvegicus	51-61
25377427-2	2015	To explore underlying mechanisms, we overexpressed PGC-1alpha, a master regulator of mitochondrial biogenesis, twofold in H9c2 rat cardiomyocyte cultures, hypothesizing that this might protect the mitochondria from damage induced by the NRTI combination zidovudine (AZT) and didanosine (ddI).	didanosine	287-290	PPARG coactivator 1 alpha	Rattus norvegicus	51-61
25377427-5	2015	Apoptosis was highest in AZT/ddI-exposed control cells, and PGC-1alpha overexpression protected cells from AZT/ddI-induced apoptosis.	didanosine	111-114	PPARG coactivator 1 alpha	Sus scrofa	60-70
25377427-6	2015	At P3, P6, P8, and P12, uncoupled mitochondrial oxygen consumption rate, determined by Seahorse 24 XF Analyzer, as higher in AZT/ddI-exposed PGC-1alpha cells, compared to AZT/ddI-exposed control cells (p < 0.05 at all P).	didanosine	129-132	PPARG coactivator 1 alpha	Sus scrofa	141-151
24976398-4	2014	Addition of guanosine to the ddI-treated cells prevented the degradation of mitochondrial TK2 and dGK.	didanosine	29-32	Diacyl glycerol kinase	Drosophila melanogaster	98-101
24976398-0	2014	Down-regulation of mitochondrial thymidine kinase 2 and deoxyguanosine kinase by didanosine: implication for mitochondrial toxicities of anti-HIV nucleoside analogs.	didanosine	81-91	deoxyguanosine kinase	Homo sapiens	56-77
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	thymidine kinase 2	Homo sapiens	226-229
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	Diacyl glycerol kinase	Drosophila melanogaster	234-237
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	deoxycytidine kinase	Homo sapiens	258-278
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	280-283
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	thymidine kinase 1	Homo sapiens	289-307
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	50-60	thymidine kinase 1	Homo sapiens	309-312
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	thymidine kinase 2	Homo sapiens	226-229
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	Diacyl glycerol kinase	Drosophila melanogaster	234-237
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	deoxycytidine kinase	Homo sapiens	258-278
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	280-283
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	thymidine kinase 1	Homo sapiens	289-307
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	62-65	thymidine kinase 1	Homo sapiens	309-312
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	thymidine kinase 2	Homo sapiens	226-229
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	Diacyl glycerol kinase	Drosophila melanogaster	234-237
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	deoxycytidine kinase	Homo sapiens	258-278
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	280-283
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	thymidine kinase 1	Homo sapiens	289-307
24976398-3	2014	Here we showed that incubation of U2OS cells with didanosine (ddI, 2",3"-dideoxyinosine), a purine nucleoside analog used in the highly active antiretroviral therapy (HAART), led to selective degradation of both mitochondrial TK2 and dGK while the cytosolic deoxycytidine kinase (dCK) and thymidine kinase 1 (TK1) were not affected.	didanosine	67-87	thymidine kinase 1	Homo sapiens	309-312
24976398-4	2014	Addition of guanosine to the ddI-treated cells prevented the degradation of mitochondrial TK2 and dGK.	didanosine	29-32	thymidine kinase 2	Homo sapiens	90-93
21658957-4	2011	Among the synthesized carbanucleosides, D-thymine nucleoside, D-2 and L-thymine nucleoside, L-2 exhibited excellent anti-HIV-1 and -2 activities, in MT-4 cells, which were higher than those of ddI, an anti-AIDS drug.	didanosine	193-196	immunoglobulin kappa variable 3-15	Homo sapiens	92-95
22469844-5	2012	When MTS-p53 cells were treated with the nucleoside reverse transcriptase inhibitor (NRTI), 2",3"-dideoxycytidine or 2",3"-dideoxyinosine, mtDNA depletion that resembled untransfected controls was observed in both instances.	didanosine	117-137	tumor protein p53	Homo sapiens	9-12
22138483-0	2012	E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.	didanosine	49-59	Vpr	Human immunodeficiency virus 1	23-26
24591154-5	2014	At P5, P7, and P13, AZT/ddI-exposed cells showed an OCR reduction of 8.8-57.2% in AZT/ddI-exposed cells, compared with unexposed cells.	didanosine	24-27	H3 histone pseudogene 6	Homo sapiens	15-18
24591154-7	2014	The Seahorse data were further supported by electron microscopy (EM) studies in which P16 cells exposed to AZT/ddI/Tempol had less mitochondrial pathology than P16 cells exposed to AZT/ddI.	didanosine	111-114	cyclin dependent kinase inhibitor 2A	Homo sapiens	86-89
24591154-7	2014	The Seahorse data were further supported by electron microscopy (EM) studies in which P16 cells exposed to AZT/ddI/Tempol had less mitochondrial pathology than P16 cells exposed to AZT/ddI.	didanosine	111-114	cyclin dependent kinase inhibitor 2A	Homo sapiens	160-163
24591154-7	2014	The Seahorse data were further supported by electron microscopy (EM) studies in which P16 cells exposed to AZT/ddI/Tempol had less mitochondrial pathology than P16 cells exposed to AZT/ddI.	didanosine	185-188	cyclin dependent kinase inhibitor 2A	Homo sapiens	160-163
23684934-8	2013	All the drugs that have been implicated in P-gp mediated DDI were found to be inhibitors in a relevant concentration range.	didanosine	57-60	phosphoglycolate phosphatase	Homo sapiens	43-47
22138483-9	2012	However, its association with TAMs and the use of didanosine was consistent with phenotypic susceptibility assays showing a significant 3-fold decrease in didanosine susceptibility of viruses harboring Vpr E17A combined with TAMs compared to viruses harboring TAMs alone.	didanosine	50-60	Vpr	Human immunodeficiency virus 1	202-205
22138483-9	2012	However, its association with TAMs and the use of didanosine was consistent with phenotypic susceptibility assays showing a significant 3-fold decrease in didanosine susceptibility of viruses harboring Vpr E17A combined with TAMs compared to viruses harboring TAMs alone.	didanosine	155-165	Vpr	Human immunodeficiency virus 1	202-205
22138483-11	2012	Vpr E17A confers resistance to didanosine when associated with TAMs.	didanosine	31-41	Vpr	Human immunodeficiency virus 1	0-3
22138483-12	2012	Whether Vpr E17A facilitates excision of didanosine is still to be determined.	didanosine	41-51	Vpr	Human immunodeficiency virus 1	8-11
21403643-13	2011	Treatment with ddI had a compensatory effect on mtDNA abundance in OAT1 KO but not in MRP4 KO.	didanosine	15-18	solute carrier family 22 member 6	Homo sapiens	67-71
21087377-7	2011	The CD4 cell count increased after treatment initiation from 176 to 497 cells/mm(3) in the ddI group and from 176 to 567 cells/mm(3) in the ZDV group (P > 0.3).	didanosine	91-94	CD4 molecule	Homo sapiens	4-7
21280612-1	2011	Five peptidomimetic prodrugs of didanosine (DDI) were synthesized and designed to improve bioavailability of DDI following oral administration via targeting intestinal oligopeptide transporter (PepT1) and enhancing chemical stability.	didanosine	32-42	solute carrier family 15 member 1	Homo sapiens	194-199
21280612-1	2011	Five peptidomimetic prodrugs of didanosine (DDI) were synthesized and designed to improve bioavailability of DDI following oral administration via targeting intestinal oligopeptide transporter (PepT1) and enhancing chemical stability.	didanosine	44-47	solute carrier family 15 member 1	Homo sapiens	194-199
21280612-17	2011	Additionally, the prodrug strategy targeted to intestinal PepT1 could offer a promising strategy to improve oral bioavailability of poorly absorbed didanosine.	didanosine	148-158	solute carrier family 15 member 1	Homo sapiens	58-63
21215124-9	2010	Furthermore, after treated with AZT + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 59.09% (13/22), meanwhile after treated with D4T + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 43.48% (10/23), which the difference was not statistical significant (chi(2) = 1.10, P = 0.30).	didanosine	38-41	C-C motif chemokine receptor 5	Homo sapiens	64-68
21215124-9	2010	Furthermore, after treated with AZT + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 59.09% (13/22), meanwhile after treated with D4T + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 43.48% (10/23), which the difference was not statistical significant (chi(2) = 1.10, P = 0.30).	didanosine	38-41	C-C motif chemokine receptor 5	Homo sapiens	162-166
20525731-3	2010	Towards this aim, we describe the engineering of human PNP to accept 2",3"-dideoxyinosine (ddI, Videx((R))) as a substrate for phosphorolysis using a combination of site-directed mutagenesis and directed evolution.	didanosine	69-89	purine nucleoside phosphorylase	Homo sapiens	55-58
19432547-3	2009	We evaluated 4 patients with a history of CD4(+) T cell decline despite successfully suppressive ART, from a median of 719 cells/mm(3) (range, 360-1141 cells/mm(3)) to 227 cells/mm(3) (range, 174-311 cells/mm(3)) over a period of 18-24 months; 3 of the patients were receiving tenofovir and didanosine, which may have contributed to this decrease.	didanosine	291-301	CD4 molecule	Homo sapiens	42-45
19380511-9	2009	These findings indicate that the beneficial effects of ddI might be a consequence of a reduced systemic viral burden and concurrent leukocyte activation, leading to diminished neuroinflammation with preservation of neuronal autophagy by regulating CXCR3 activation.	didanosine	55-58	C-X-C motif chemokine receptor 3	Homo sapiens	248-253
20453628-0	2010	Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.	didanosine	13-23	integrin subunit alpha M	Homo sapiens	102-107
20453628-7	2010	Both abacavir and didanosine increased Mac-1 expression in neutrophils and monocytes, but produced no effects on either lymphocytes or the expression of endothelial adhesion molecules.	didanosine	18-28	integrin subunit alpha M	Homo sapiens	39-44
19737231-8	2009	The proportion of CD4(+)CD45RA(+) T cells and of functionally inhibited killer immunoglobulin-like receptor T cell receptor alphabeta(+) cells, the proliferation to recall antigens as well as NK cell phenotype and function as determined by interferon-gamma production in patients treated with tenofovir-didanosine were comparable to those treated with a different regimen.	didanosine	303-313	CD4 molecule	Homo sapiens	18-21
19237894-0	2009	Lower circulating Sta-Liatest D-Di levels in patients with aortic intramural hematoma compared with classical aortic dissection.	didanosine	30-34	GCY	Homo sapiens	18-21
19218343-4	2009	Five other HAART drugs (indinavir, lamivudine, abacavir, AZT, and ddI) and the 3-plex significantly also impaired endothelium-dependent vasorelaxation in response to bradykinin.	didanosine	66-69	kininogen 1	Homo sapiens	166-176
19237894-14	2009	CONCLUSIONS: Sta-Liatest D-Di levels are lower in AIH than in AAD with patent false lumen.	didanosine	25-29	GCY	Homo sapiens	13-16
19207595-7	2009	Lower CD4 increases were observed in patients exposed to didanosine (ddI) or a combination of ddI and stavudine, although the difference was not statistically significant.	didanosine	57-67	CD4 molecule	Homo sapiens	6-9
19207595-7	2009	Lower CD4 increases were observed in patients exposed to didanosine (ddI) or a combination of ddI and stavudine, although the difference was not statistically significant.	didanosine	69-72	CD4 molecule	Homo sapiens	6-9
19207595-7	2009	Lower CD4 increases were observed in patients exposed to didanosine (ddI) or a combination of ddI and stavudine, although the difference was not statistically significant.	didanosine	94-97	CD4 molecule	Homo sapiens	6-9
19135251-4	2009	Although ddI is a substrate of several transporters, including equilibrative nucleoside transporters (ENT1 and ENT2), the transport mechanism of ddI in the placenta has not yet been characterized.	didanosine	9-12	solute carrier family 29 member 1	Rattus norvegicus	102-106
18546331-6	2008	COMT inhibition combined with LD/DDI improves absorption of a co-administered salt probably due to a COMT inhibition induced basic environment in gastrointestinal membranes.	didanosine	33-36	catechol-O-methyltransferase	Homo sapiens	101-105
18541728-5	2008	mtRNA (MTCYB) was also significantly decreased in the myoblasts and myotubes treated with ddI (P = 0.004) and ddI-containing regimens (P < 0.001).	didanosine	90-93	mitochondrially encoded cytochrome b	Homo sapiens	7-12
18541728-5	2008	mtRNA (MTCYB) was also significantly decreased in the myoblasts and myotubes treated with ddI (P = 0.004) and ddI-containing regimens (P < 0.001).	didanosine	110-113	mitochondrially encoded cytochrome b	Homo sapiens	7-12
18025882-7	2007	RESULTS: After adjusting for age, gender and current CD4 cell count, hyperlactataemia/lactic acidosis remained associated with exposure to didanosine in every category of exposure duration but was most strongly associated with exposure < 12 months.	didanosine	139-149	CD4 molecule	Homo sapiens	53-56
18546542-7	2008	Patients with a lower CD4+ cell count at baseline and those starting HAART with a didanosine-based regimen had a higher increase in CD4+ cell count at six months.	didanosine	82-92	CD4 molecule	Homo sapiens	22-25
18546542-7	2008	Patients with a lower CD4+ cell count at baseline and those starting HAART with a didanosine-based regimen had a higher increase in CD4+ cell count at six months.	didanosine	82-92	CD4 molecule	Homo sapiens	132-135
18174163-8	2008	The combined observations suggest SLC22a8 (Oat3) is the major transporter interacting with ddC and ddI.	didanosine	99-102	solute carrier family 22 (organic anion transporter), member 8	Mus musculus	43-47
17434879-1	2007	BACKGROUND: Tenofovir with full-dose didanosine has been associated with paradoxical CD4 + T cell decrease despite virological suppression.	didanosine	37-47	CD4 molecule	Homo sapiens	85-88
17616550-0	2007	Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression.	didanosine	0-10	neurotrophin 3	Homo sapiens	93-112
17341536-6	2007	DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity.	didanosine	249-259	CD4 molecule	Homo sapiens	36-39
17358029-2	2007	Three-day treatments with 0, 33, 100, or 300 microM ddI, 3TC, or ddI-3TC produced positive trends for increased HPRT and TK mutant frequencies.	didanosine	52-55	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	112-116
17341536-1	2007	OBJECTIVE: To describe a case of significant CD4+ cell decline despite complete viral suppression in an HIV-positive patient receiving didanosine and valganciclovir.	didanosine	135-145	CD4 molecule	Homo sapiens	45-48
17341536-11	2007	CONCLUSIONS: Patients receiving didanosine-containing highly active antiretroviral therapy and ganciclovir or valganciclovir for treatment of CMV infection should be monitored for didanosine toxicity and unexpected CD4+ cell loss or failure of CD4+ cell recovery.	didanosine	32-42	CD4 molecule	Homo sapiens	215-218
17341536-5	2007	Didanosine was replaced with abacavir, leading to a complete CD4+ cell recovery and resolution of symptoms.	didanosine	0-10	CD4 molecule	Homo sapiens	61-64
17341536-11	2007	CONCLUSIONS: Patients receiving didanosine-containing highly active antiretroviral therapy and ganciclovir or valganciclovir for treatment of CMV infection should be monitored for didanosine toxicity and unexpected CD4+ cell loss or failure of CD4+ cell recovery.	didanosine	32-42	CD4 molecule	Homo sapiens	244-247
17341536-6	2007	DISCUSSION: Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity.	didanosine	129-139	CD4 molecule	Homo sapiens	36-39
16956530-1	2006	BACKGROUND: Several recent studies have shown that the combination of ddI plus TDF can produce an unexpected drop in CD4 cell counts, even after correcting the ddI dose.	didanosine	70-73	CD4 molecule	Homo sapiens	117-120
16940060-8	2006	The effects of ddI, but not those of AZT, on mtDNA and COII mRNA were further enhanced in the presence of TFV, a finding consistent with the inhibition of ddI clearance by TFV.	didanosine	15-18	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	55-59
16940060-9	2006	The addition of TFV to ddI or AZT appeared to slightly increase the COII mRNA/mtDNA ratio relative to that in cells treated with ddI or AZT alone.	didanosine	23-26	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	68-72
16956530-1	2006	BACKGROUND: Several recent studies have shown that the combination of ddI plus TDF can produce an unexpected drop in CD4 cell counts, even after correcting the ddI dose.	didanosine	160-163	CD4 molecule	Homo sapiens	117-120
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	didanosine	132-135	CD4 molecule	Homo sapiens	36-39
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	didanosine	163-166	CD4 molecule	Homo sapiens	36-39
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	didanosine	163-166	CD4 molecule	Homo sapiens	174-177
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	didanosine	163-166	CD4 molecule	Homo sapiens	36-39
16956530-9	2006	In patients treated with TDF + 3TC, CD4 count increased by 160 cel/microl (95% CI, 53-266) more than in patients treated with TDF + ddI; and in patients receiving ddI + 3TC, CD4+ count increased by 138 cel/microl (95% CI, 25-266) more than in patients receiving TDF + ddI.	didanosine	163-166	CD4 molecule	Homo sapiens	174-177
16623622-1	2006	Coadministration of didanosine (ddI) and tenofovir (TDF) results in increased ddI serum concentrations, which may lead to increased risk of ddI-associated toxicities.	didanosine	78-81	sex determining region Y	Homo sapiens	52-55
16717052-0	2006	Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.	didanosine	68-78	CD4 molecule	Homo sapiens	23-26
16531427-0	2006	Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.	didanosine	56-66	CD4 molecule	Homo sapiens	11-14
16531427-4	2006	As an example, the combination of didanosine and tenofovir has recently been associated with a paradoxical depletion of CD4+ T cells in the face of complete viral suppression.	didanosine	34-44	CD4 molecule	Homo sapiens	120-123
16107993-1	2005	The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 versus Optimized Regimen Only [TORO] 1 and 2 clinical trials).	didanosine	68-78	CD4 molecule	Homo sapiens	95-98
16306034-3	2005	Given that TDF is an adenosine analogue, like didanosine, exposure to ribavirin might increase intracellular phosphorylated TDF metabolites, which could result in a higher risk of nephrotoxicity.	didanosine	46-56	sex determining region Y	Homo sapiens	124-127
15865227-4	2005	RESULTS: In CD4 lymphocytes, 10-day exposure to zalcitabine (1.77 microM), didanosine (118 microM) and stavudine (361 microM) induced a time-dependent decline of mtDNA.	didanosine	75-85	CD4 molecule	Homo sapiens	12-15
15958845-0	2005	Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.	didanosine	70-80	CD4 molecule	Homo sapiens	17-20
15958845-1	2005	In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed.	didanosine	67-77	CD4 molecule	Homo sapiens	31-34
15958845-3	2005	Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.	didanosine	94-104	CD4 molecule	Homo sapiens	29-32
15958845-3	2005	Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.	didanosine	133-143	CD4 molecule	Homo sapiens	29-32
15802975-0	2005	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.	didanosine	110-120	CD4 molecule	Homo sapiens	12-15
16247988-2	2005	In order to present the dideoxynucleosides as pre-activated nucleotides and bypass the kinase, as well as to prevent their metabolism to dideoxyinosine by adenosine deaminase, the aryloxyphosphoramidate approach has been successfully applied, initially on the 2",3"-ddA.	didanosine	137-151	adenosine deaminase	Oryctolagus cuniculus	155-174
16312178-13	2005	Moreover, CD4+ cell declines in the QD arm were significantly greater in patients taking high versus low didanosine doses (-59 versus -15 cells/microl; P=0.04).	didanosine	105-115	CD4 molecule	Homo sapiens	10-13
15622326-0	2004	CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.	didanosine	22-32	CD4 molecule	Homo sapiens	0-3
15259896-13	2004	Combination of standard doses of didanosine and tenofovir may have contributed to the CD4 cell decline observed with this QD regimen.	didanosine	33-43	CD4 molecule	Homo sapiens	86-89
15215330-0	2004	Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine.	didanosine	119-129	hypoxanthine guanine phosphoribosyl transferase	Mus musculus	20-24
15047506-0	2004	Role of purine nucleoside phosphorylase in interactions between 2",3"-dideoxyinosine and allopurinol, ganciclovir, or tenofovir.	didanosine	64-84	purine nucleoside phosphorylase	Homo sapiens	8-39
15037197-11	2004	However, this conversion renders hENT1 less sensitive to inhibition by anti-HIV drugs azidothymidine, dideoxyinosine, and the nucleobase, hypoxanthine.	didanosine	102-116	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	33-38
15090798-0	2004	Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.	didanosine	56-66	CD4 molecule	Homo sapiens	11-14
15090798-1	2004	BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression.	didanosine	92-102	CD4 molecule	Homo sapiens	47-50
15090798-1	2004	BACKGROUND: We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression.	didanosine	104-107	CD4 molecule	Homo sapiens	47-50
14706628-0	2004	Structures of human purine nucleoside phosphorylase complexed with inosine and ddI.	didanosine	79-82	purine nucleoside phosphorylase	Homo sapiens	20-51
15476197-2	2004	We previously reported extraordinary increases in micronucleated erythrocytes in CD-1 mouse pups exposed to 3"-azido-3"-deoxythymidine (AZT) and dideoxyinosine (ddI; 50/250, 75/375, 150/750 mg/kg/day AZT/ddI) by gavage throughout gestation and lactation, followed by direct pup dosing beginning postnatal day (PND) 4 (Bishop et al.	didanosine	204-207	CD1 antigen complex	Mus musculus	81-85
11101059-9	2000	Mean changes in CD4+ cell counts for patients treated with stavudine plus once- or twice-daily didanosine and nevirapine were 154 and 132 x 10(6) cells/l, respectively.	didanosine	95-105	CD4 molecule	Homo sapiens	16-19
14743340-0	2004	Genetic damage detected in CD-1 mouse pups exposed perinatally to 3"-azido-3"-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage.	didanosine	97-111	CD1 antigen complex	Mus musculus	27-31
14715401-3	2004	Peripheral administration of inhibitors of protein kinase A, protein kinase C, protein kinase G, p42/p44-mitogen-activated protein kinase (ERK1/2) and nitric oxide synthase, which have demonstrated anti-hyperalgesic effects in other models of metabolic and toxic painful peripheral neuropathies, had no effect on ddC-, ddI- and d4T-induced hypersensitivity.	didanosine	319-322	mitogen activated protein kinase 3	Rattus norvegicus	139-145
14685050-6	2003	CXCR4-using virus was present from the onset (five patients) or appeared during clinical progression in all other patients, while taking zidovudine or didanosine monotherapy.	didanosine	151-161	C-X-C motif chemokine receptor 4	Homo sapiens	0-5
12021329-3	2002	CD95-mediated death did not depend on CD4 T-cell infection, since it occurred in the presence of the reverse transcriptase inhibitor didanosine (ddI).	didanosine	133-143	Fas cell surface death receptor	Homo sapiens	0-4
12021329-3	2002	CD95-mediated death did not depend on CD4 T-cell infection, since it occurred in the presence of the reverse transcriptase inhibitor didanosine (ddI).	didanosine	145-148	Fas cell surface death receptor	Homo sapiens	0-4
11602688-10	2001	These studies provide evidence for asymmetric transport sites on rat CNT2, where 2",3"-dideoxyinosine and thymidine compete selectively at a low Vmax site on the transporter, whereas adenosine is transported at a high Vmax site.	didanosine	81-101	solute carrier family 28 member 2	Rattus norvegicus	69-73
11090748-1	2000	BACKGROUND: The Murex-Innogenetics LiPA HIV-1 RT assay can be used to identify the presence of mutations of the reverse transcriptase gene at codons 41, 69, 70, 74, 184 and 215 of HIV-1, which have been shown to confer resistance to the nucleoside analogs Zidovudine (ZDV), Lamivudine (3TC), Didanosine (ddI) and Zalcitabine (ddC).	didanosine	292-302	lipase A, lysosomal acid type	Homo sapiens	35-39
11090748-1	2000	BACKGROUND: The Murex-Innogenetics LiPA HIV-1 RT assay can be used to identify the presence of mutations of the reverse transcriptase gene at codons 41, 69, 70, 74, 184 and 215 of HIV-1, which have been shown to confer resistance to the nucleoside analogs Zidovudine (ZDV), Lamivudine (3TC), Didanosine (ddI) and Zalcitabine (ddC).	didanosine	304-307	lipase A, lysosomal acid type	Homo sapiens	35-39
15476197-2	2004	We previously reported extraordinary increases in micronucleated erythrocytes in CD-1 mouse pups exposed to 3"-azido-3"-deoxythymidine (AZT) and dideoxyinosine (ddI; 50/250, 75/375, 150/750 mg/kg/day AZT/ddI) by gavage throughout gestation and lactation, followed by direct pup dosing beginning postnatal day (PND) 4 (Bishop et al.	didanosine	145-159	CD1 antigen complex	Mus musculus	81-85
15476197-2	2004	We previously reported extraordinary increases in micronucleated erythrocytes in CD-1 mouse pups exposed to 3"-azido-3"-deoxythymidine (AZT) and dideoxyinosine (ddI; 50/250, 75/375, 150/750 mg/kg/day AZT/ddI) by gavage throughout gestation and lactation, followed by direct pup dosing beginning postnatal day (PND) 4 (Bishop et al.	didanosine	161-164	CD1 antigen complex	Mus musculus	81-85
14581168-7	2003	These results indicate that zinc benzoate, which inhibits MAO-A activity, is easily incorporated in DDI water by boiling polystyrene and also may be a contaminating environmental chemical compound that alters the levels of serotonin and norepinephrine in the central nervous system.	didanosine	100-103	monoamine oxidase A	Rattus norvegicus	58-63
12803944-10	2003	The results support the need for a randomized, prospective study to determine the safety and efficacy of hydroxyurea plus didanosine in antiretroviral-experienced patients with CD4(+) cell counts below 300 cells/mm(3).	didanosine	122-132	CD4 molecule	Homo sapiens	177-180
12215207-7	2002	Apoptotic CD4 and CD8 cells, lymphocytes with disrupted mitochondrial membrane potential, and lymphocytes undergoing oxidant stress were greatly reduced in subjects treated with AZT and DDI plus L-carnitine compared with those who did not receive L-carnitine.	didanosine	186-189	CD4 molecule	Homo sapiens	10-13
12215207-7	2002	Apoptotic CD4 and CD8 cells, lymphocytes with disrupted mitochondrial membrane potential, and lymphocytes undergoing oxidant stress were greatly reduced in subjects treated with AZT and DDI plus L-carnitine compared with those who did not receive L-carnitine.	didanosine	186-189	CD8a molecule	Homo sapiens	18-21
12034036-1	2002	We wished to evaluate the efficacy and safety of a low and an intermediate daily dose of interferon-alpha2b (IFN-alpha2b) with didanosine in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi"s sarcoma (KS).	didanosine	127-137	interferon alpha 2	Homo sapiens	89-107
12034036-1	2002	We wished to evaluate the efficacy and safety of a low and an intermediate daily dose of interferon-alpha2b (IFN-alpha2b) with didanosine in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi"s sarcoma (KS).	didanosine	127-137	interferon alpha 1	Homo sapiens	109-112
11865396-0	2002	T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.	didanosine	148-158	CD4 molecule	Homo sapiens	122-125
12112380-4	2002	The purpose of the current study was to characterize the mutational specificity of equimolar mixtures of 100 microM or 300 microM AZT + ddI at the HPRT and TK loci of exposed cells vs. unexposed control cells, and to compare the resulting mutational spectra data to those previously found in cells exposed to AZT alone (Sussman H et al.	didanosine	136-139	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	147-151
12112380-13	2002	In addition, cotreatments of ddI with AZT led to substantial absolute increases in the mutant fraction of other classes of mutations, unlike cells exposed solely to AZT [e.g., the frequency of point mutations among HPRT mutants was significantly increased by 130 and 323% over the background value (4.25 x 10(-6)) in cells exposed to 100 and 300 microM AZT-ddI, respectively].	didanosine	29-32	hypoxanthine phosphoribosyltransferase 1	Homo sapiens	215-219
11602688-0	2001	Differential kinetics of transport of 2",3"-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier.	didanosine	38-58	solute carrier family 28 member 2	Rattus norvegicus	118-122
11602688-2	2001	This high activity of the rat CNT2 produced from the blood-brain barrier-derived cDNA, designated clone A-11, enabled a kinetic analysis of 2",3"-dideoxyinosine transport via the rat CNT2.	didanosine	140-160	solute carrier family 28 member 2	Rattus norvegicus	30-34
11602688-2	2001	This high activity of the rat CNT2 produced from the blood-brain barrier-derived cDNA, designated clone A-11, enabled a kinetic analysis of 2",3"-dideoxyinosine transport via the rat CNT2.	didanosine	140-160	solute carrier family 28 member 2	Rattus norvegicus	183-187
11602688-3	2001	CNT2 transported both adenosine and 2",3"-dideoxyinosine.	didanosine	36-56	solute carrier family 28 member 2	Rattus norvegicus	0-4
10613402-4	1999	The higher concentration of AZT and ddI produced significant (P < 0.025) reductions in cell numbers and growth rate while producing significant increases in hormone production (hCG, E2, and P4).	didanosine	36-39	hypertrichosis 2 (generalised, congenital)	Homo sapiens	180-183
10945832-7	2000	Five other antiviral agents that we studied (zalcitabine, didanosine, lamivudine, stavudine, and trifluridine) were also shown to be transported by rOAT1, whereas foscarnet, a phosphate analog, was not.	didanosine	58-68	solute carrier family 22 member 6	Rattus norvegicus	148-153
10671348-1	2000	We report the evolution of chronic infection with human immunodeficiency virus type 1 (HIV-1) in a patient treated with stavudine plus didanosine, whose CD4+ lymphocyte count progressively decreased, despite a sustained plasma viral load <20 copies/mL.	didanosine	135-145	CD4 molecule	Homo sapiens	153-156
10651392-4	1999	In numerous clinical trials, pronounced and sustained decreases in plasma HIV RNA levels and increases in CD4+ cell counts occurred in previously untreated or antiretroviral therapy-experienced patients treated with didanosine in combination with at least 1 other antiretroviral drug; zidovudine, stavudine, lamivudine, nevirapine, nelfinavir and hydroxyurea (hydroxycarbamide) are among the drugs that have been given in combination with didanosine.	didanosine	216-226	CD4 molecule	Homo sapiens	106-109
10651392-4	1999	In numerous clinical trials, pronounced and sustained decreases in plasma HIV RNA levels and increases in CD4+ cell counts occurred in previously untreated or antiretroviral therapy-experienced patients treated with didanosine in combination with at least 1 other antiretroviral drug; zidovudine, stavudine, lamivudine, nevirapine, nelfinavir and hydroxyurea (hydroxycarbamide) are among the drugs that have been given in combination with didanosine.	didanosine	439-449	CD4 molecule	Homo sapiens	106-109
10515813-4	1999	The same oral dose of ddI (bid) was administered until labor began.	didanosine	22-25	BH3 interacting domain death agonist	Homo sapiens	27-30
10428106-8	1999	In this study, therapy with delavirdine + zidovudine + didanosine was safe and showed modest, but not always significant, antiviral activity and CD4 cell count benefit compared with two-drug regimens with these agents.	didanosine	55-65	CD4 molecule	Homo sapiens	145-148
10534145-0	1999	Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.	didanosine	46-56	CD4 molecule	Homo sapiens	112-115
10395849-5	1999	The combination of stavudine plus didanosine reduced plasma HIV-1 RNA concentrations and increased CD4 cell counts more effectively than did the combination of zidovudine plus lamivudine or the regimen alternating both combinations.	didanosine	34-44	CD4 molecule	Homo sapiens	99-102
10052756-0	1999	Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.	didanosine	10-20	protein tyrosine phosphatase receptor type C	Homo sapiens	73-77
10386939-0	1999	Lipase-catalyzed protection of the hydroxy groups of the nucleosides inosine and 2"-deoxyinosine: a new chemoenzymatic synthesis of the antiviral drug 2",3"-dideoxyinosine.	didanosine	151-171	PAN0_003d1715	Moesziomyces antarcticus	0-6
16021874-5	1999	Stavudine/didanosine was associated with a mean increase in CD4 cell count (124 cells/mm3) significantly greater than that in the zidovudine/lamivudine group (62 cells/mm3, P<0.01) and comparable to that in the alternating group (118 cells/mm3).	didanosine	10-20	CD4 molecule	Homo sapiens	60-63
16021880-6	1999	A pilot study to assess the antiviral effect of a combination of didanosine plus stavudine plus nevirapine with or without hydroxyurea in the treatment of PHI is currently under way.	didanosine	65-75	glucose-6-phosphate isomerase	Homo sapiens	155-158
9928724-7	1999	This study demonstrates that a triple combination of ZDV + ddI + nevirapine used as first-line regimen in antiretroviral-naive patients can induce sustained virologic and immunologic response in patients with low CD4 count or a previous diagnosis of AIDS.	didanosine	59-62	CD4 molecule	Homo sapiens	213-216
9708405-1	1998	OBJECTIVE: To analyse the relationship between CD8+ lymphocyte phenotype alterations and plasma HIV RNA levels in HIV-infected patients treated with the zidovudine-didanosine combination.	didanosine	164-174	CD8a molecule	Homo sapiens	47-50
9863862-1	1998	OBJECTIVE: To compare the plasma pharmacokinetics of didanosine during once daily (qd) and twice daily (bid) dosing.	didanosine	53-63	BH3 interacting domain death agonist	Homo sapiens	104-107
10087507-10	1998	hCNT2 also mediated small, but significant, fluxes of the antiviral purine nucleoside analogue 2",3"-dideoxyinosine.	didanosine	95-115	solute carrier family 28 member 2	Homo sapiens	0-5
9572907-7	1998	Extensive intracellular metabolism of 6-Cl-ddP by ADA was confirmed by the high concentrations of ddI found both in the intestinal lumen and blood during 6-Cl-ddP perfusions and by a rate of ddI appearance in blood which was approximately 10-fold higher than ddI controls.	didanosine	98-101	adenosine deaminase	Rattus norvegicus	50-53
9572907-0	1998	Absorption and intestinal metabolism of purine dideoxynucleosides and an adenosine deaminase-activated prodrug of 2",3"-dideoxyinosine in the mesenteric vein cannulated rat ileum.	didanosine	114-134	adenosine deaminase	Rattus norvegicus	73-92
9572907-7	1998	Extensive intracellular metabolism of 6-Cl-ddP by ADA was confirmed by the high concentrations of ddI found both in the intestinal lumen and blood during 6-Cl-ddP perfusions and by a rate of ddI appearance in blood which was approximately 10-fold higher than ddI controls.	didanosine	191-194	adenosine deaminase	Rattus norvegicus	50-53
9168161-9	1997	AZT, ddI and ddC induced cytoplasmic lipid droplet accumulations, increased lactate production and decreased activities of COX (complex IV) and SDH (part of complex II).	didanosine	5-8	cytochrome c oxidase subunit 5A	Homo sapiens	123-126
9572907-4	1998	Values of Pblood for ddI were determined to be (1.1 +/- 0.3) x 10(-6) cm/s, in close agreement with the value of (1.0 +/- 0.3) x 10(-6) cm/s obtained for F-ddI, a PNP resistant analogue of ddI having virtually the same molecular size and lipophilicity as ddI.	didanosine	21-24	purine nucleoside phosphorylase	Rattus norvegicus	163-166
10503166-21	1998	Subsequent to this study, a trial of lentinan in combination with didanosine (ddI) showed a mean increase of 142 CD4 cells/mm3 over a twelve month period, in contrast to a decrease in CD4 cells in patients on ddI alone (Gordon et al.	didanosine	66-76	CD4 molecule	Homo sapiens	113-116
10503166-21	1998	Subsequent to this study, a trial of lentinan in combination with didanosine (ddI) showed a mean increase of 142 CD4 cells/mm3 over a twelve month period, in contrast to a decrease in CD4 cells in patients on ddI alone (Gordon et al.	didanosine	78-81	CD4 molecule	Homo sapiens	113-116
11327443-12	1997	Our data confirm a clinical benefit and CD4 increase associated with a switch from zidovudine to didanosine therapy.	didanosine	97-107	CD4 molecule	Homo sapiens	40-43
9463485-9	1998	The antiviral analogs dideoxyinosine and arabinosyl adenine also showed significant activity with dGK, as did several pyrimidine analogs (e.g., the cytostatic drugs 5-fluoro-2"-deoxycytidine and difluorodeoxycytidine).	didanosine	22-36	Diacyl glycerol kinase	Drosophila melanogaster	98-101
9168161-9	1997	AZT, ddI and ddC induced cytoplasmic lipid droplet accumulations, increased lactate production and decreased activities of COX (complex IV) and SDH (part of complex II).	didanosine	5-8	cytochrome c oxidase subunit 5A	Homo sapiens	128-138
8997487-13	1996	Latest clinical results show, however, promisingly that both problems might be overcome by application of the PI in combination with RT inhibitors (such as AZT, ddI or ddC) exerting a remarkable synergistic antiviral effect with lasting restoration of the CD4-T-cell level.	didanosine	161-164	CD4 molecule	Homo sapiens	256-259
9098877-7	1997	A comparison of the model-predicted plasma concentration-time profiles with the observed profiles in AIDS patients who often received ddI with pentamidine showed that the ddI model underestimated the terminal half-life (t1/2, beta) by 39% whereas the ddI + pentamidine model yielded identical t1/2, beta and area-under-the-curve as the observed values (< 1% deviation).	didanosine	171-174	interleukin 1 receptor like 1	Homo sapiens	220-230
9098877-7	1997	A comparison of the model-predicted plasma concentration-time profiles with the observed profiles in AIDS patients who often received ddI with pentamidine showed that the ddI model underestimated the terminal half-life (t1/2, beta) by 39% whereas the ddI + pentamidine model yielded identical t1/2, beta and area-under-the-curve as the observed values (< 1% deviation).	didanosine	171-174	interleukin 1 receptor like 1	Homo sapiens	293-303
11322267-9	1997	Finally, the CD4:CD8 ratio was significantly higher in the zidovudine-didanosine group and none of the patients in this group developed HIV-1-associated clinical complications.	didanosine	70-80	CD4 molecule	Homo sapiens	13-16
11322267-9	1997	Finally, the CD4:CD8 ratio was significantly higher in the zidovudine-didanosine group and none of the patients in this group developed HIV-1-associated clinical complications.	didanosine	70-80	CD8a molecule	Homo sapiens	17-20
9586055-3	1997	They are converted to ddG and ddI, respectively, by adenosine deaminase in the cells, and express their anti-HIV activity in vitro.	didanosine	30-33	adenosine deaminase	Mus musculus	52-71
11322250-3	1996	During the first 3 months on didanosine therapy, the increase in CD4 cell counts was greater in patients who were wild type at codon 215 than in those with the mutation at codon 215 (P = 0.03).	didanosine	29-39	CD4 molecule	Homo sapiens	65-68
8898668-2	1996	A phase-I study was conducted to examine the safety, pharmacokinetics, and activity of combination 2",3"-dideoxyinosine (ddI) and ribavirin against human immunodeficiency virus type 1 (HIV-1)-positive individuals with CD4+ cell counts of < or = 500/microliter.	didanosine	99-119	CD4 molecule	Homo sapiens	218-221
8898668-13	1996	CD4+ cell counts increased above baseline significantly during the ddI-monotherapy phase of the study (p = 0.0038).	didanosine	67-70	CD4 molecule	Homo sapiens	0-3
8947968-8	1996	Nucleoside and P-glycoprotein transporters appear to play an important role in renal tubular transport of dideoxynucleosides (e.g., zidovudine, dideoxyinosine) and digoxin, respectively.	didanosine	144-158	ATP binding cassette subfamily B member 1	Homo sapiens	15-29
11322250-4	1996	These data suggest that there was a better initial CD4 response to didanosine therapy in patients with HIV without the mutation at codon 215, but that this response did not translate into increased survival.	didanosine	67-77	CD4 molecule	Homo sapiens	51-54
8603961-6	1996	CD4 cell counts increased with didanosine but declined following the addition of IFN-alpha; CD4 cell percents tended to increase and remain elevated.	didanosine	31-41	CD4 molecule	Homo sapiens	0-3
8673528-11	1996	In the didanosine 500 mg group, more patients had a 50% increase in CD4 cells (10% vs. 1% in zidovudine group, p = 0.01) and an increase of > or = 2.5 kg in body weight (2% versus 3%).	didanosine	7-17	CD4 molecule	Homo sapiens	68-71
8605592-2	1996	The combination of didanosine and zidovudine resulted in a more pronounced increase of CD4 cells over time compared to the combination of dideoxicytidine with zidovudine (p < 0.002).	didanosine	19-29	CD4 molecule	Homo sapiens	87-90
8605592-6	1996	The present study favors the combination of didanosine and zidovudine in patients deteriorating while receiving zidovudine for > 24 weeks in respect to the time course of the CD4 cells.	didanosine	44-54	CD4 molecule	Homo sapiens	178-181
8545317-9	1995	Increasing use of somatostatin, particularly in HIV patients often given other hyperglycaemia inducing drugs such as didanosine, pentamidine, dapsone, and phenytoin should be accompanied with careful monitoring of blood glucose levels.	didanosine	117-127	somatostatin	Homo sapiens	18-30
8556398-5	1996	At 2 months, the difference in mean CD4 count from baseline was +15.4 cells/mm3 in the ddI group but -1.3 cells/mm3 in the ddC group.	didanosine	87-90	CD4 molecule	Homo sapiens	36-39
8556398-6	1996	Patients assigned to ddI had a greater chance of a CD4 response at 2 months than those on ddC, yet only those in the ddC group with a response showed significant improvement in progression of disease or survival compared with ddC nonresponders, ddI responders, and ddI nonresponders (p = 0.03).	didanosine	21-24	CD4 molecule	Homo sapiens	51-54
7677296-0	1995	Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3.	didanosine	0-10	CD4 molecule	Homo sapiens	96-99
7677296-13	1995	A change to didanosine led to a statistically significant increase in CD4 counts by week 2 that persisted until the end of the study at week 48 (P < or = 0.01).	didanosine	12-22	CD4 molecule	Homo sapiens	70-73
7677296-18	1995	CONCLUSION: In clinically stable patients with 200 to 500 CD4 cells/mm3 who had tolerated zidovudine for at least 6 months, a change to didanosine led to a decrease in the rate of disease progression, a sustained increase in CD4 counts, and a decrease in the chances of developing high-level resistance to zidovudine.	didanosine	136-146	CD4 molecule	Homo sapiens	58-61
7677296-18	1995	CONCLUSION: In clinically stable patients with 200 to 500 CD4 cells/mm3 who had tolerated zidovudine for at least 6 months, a change to didanosine led to a decrease in the rate of disease progression, a sustained increase in CD4 counts, and a decrease in the chances of developing high-level resistance to zidovudine.	didanosine	136-146	CD4 molecule	Homo sapiens	225-228
8590388-3	1995	In human lymphoid cells ddAdo is converted to the active metabolite, ddATP, but it also undergoes rapid deamination, via adenosine deaminase, to form ddIno.	didanosine	150-155	adenosine deaminase	Homo sapiens	121-140
7751692-2	1995	Beginning in 1992, patients with decreases in CD4 cell counts could switch to a combination of zidovudine and didanosine.	didanosine	110-120	CD4 molecule	Homo sapiens	46-49
7494823-0	1995	Enhanced oral bioavailability of DDI after administration of 6-Cl-ddP, an adenosine deaminase-activated prodrug, to chronically catheterized rats.	didanosine	33-36	adenosine deaminase	Rattus norvegicus	74-93
7494823-1	1995	PURPOSE: 6-Cl-2",3"-dideoxypurine (6-Cl-ddP), an adenosine deaminase (ADA) activated prodrug of ddI, may be an effective antiretroviral agent for the treatment of AIDS dementia due to its ability to deliver increased concentrations of ddI to brain tissue.	didanosine	96-99	adenosine deaminase	Rattus norvegicus	49-68
7494823-1	1995	PURPOSE: 6-Cl-2",3"-dideoxypurine (6-Cl-ddP), an adenosine deaminase (ADA) activated prodrug of ddI, may be an effective antiretroviral agent for the treatment of AIDS dementia due to its ability to deliver increased concentrations of ddI to brain tissue.	didanosine	96-99	adenosine deaminase	Rattus norvegicus	70-73
7494823-7	1995	The appearance of > 50% of the dose as ddI in the systemic circulation after an oral dose of 6-Cl-ddP rules out poor absorption of the prodrug, and confirms expectations of high ADA activity in the gastrointestinal tract.	didanosine	42-45	adenosine deaminase	Rattus norvegicus	181-184
7475901-5	1995	As expected, didanosine (ddI) was less toxic for human hematopoietic progenitor cells, i.e., CFU-GEMM, CFU-GM, CFU-Meg, and BFU-E than zidovudine.	didanosine	25-28	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	115-118
7718186-9	1995	CONCLUSIONS: In patients treated with ddI, changes in viraemia at 1 month predict survival independently of initial AIDS diagnosis and initial CD4 counts.	didanosine	38-41	CD4 molecule	Homo sapiens	143-146
8595509-10	1995	In clinical studies, AZT/ddI in combination, tended to have a more positive effect on CD4 cell count than the AZT/ddC combination, although the difference was statistically significant only when baseline CD4 count was greater than 100 cells/mm3.	didanosine	25-28	CD4 molecule	Homo sapiens	86-89
8595509-10	1995	In clinical studies, AZT/ddI in combination, tended to have a more positive effect on CD4 cell count than the AZT/ddC combination, although the difference was statistically significant only when baseline CD4 count was greater than 100 cells/mm3.	didanosine	25-28	CD4 molecule	Homo sapiens	204-207
7475901-0	1995	Influence of human granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein (PIXY321) on the hematopoietic toxicity associated with anti-viral drugs (zidovudine and didanosine) in vitro using normal human marrow cells.	didanosine	186-196	interleukin 3	Homo sapiens	68-81
7475901-5	1995	As expected, didanosine (ddI) was less toxic for human hematopoietic progenitor cells, i.e., CFU-GEMM, CFU-GM, CFU-Meg, and BFU-E than zidovudine.	didanosine	13-23	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	115-118
7840911-6	1994	In a dose-ranging study of didanosine, 30% of children showed an increase in CD4 cell counts and gained weight.	didanosine	27-37	CD4 molecule	Homo sapiens	77-80
7848591-1	1994	OBJECTIVE: To evaluate the effect of liposome encapsulation on the in vitro antiviral efficacy, intracellular uptake and in vivo pharmacokinetics of 2",3"-dideoxyinosine (ddl).	didanosine	149-169	POU domain, class 4, transcription factor 3	Mus musculus	171-174
8721897-0	1995	A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.	didanosine	85-95	CD4 molecule	Homo sapiens	123-126
8721897-0	1995	A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3.	didanosine	97-100	CD4 molecule	Homo sapiens	123-126
8721897-1	1995	This study was carried out to assess the safety and efficacy of a combination of lentinan, an immune modulator, and didanosine (ddI) in a controlled study in HIV positive patients with CD4 levels of 200-500 cells/mm3.	didanosine	116-126	CD4 molecule	Homo sapiens	185-188
8721897-1	1995	This study was carried out to assess the safety and efficacy of a combination of lentinan, an immune modulator, and didanosine (ddI) in a controlled study in HIV positive patients with CD4 levels of 200-500 cells/mm3.	didanosine	128-131	CD4 molecule	Homo sapiens	185-188
7888537-5	1994	The results of this program demonstrated that patients with CD4 lymphocyte counts of < 0.10 x 10(9)/L or with a diagnosis of AIDS (defined by the 1987 classification system of the Centers for Disease Control and Prevention) were less tolerant of didanosine and significantly more likely to develop adverse clinical reactions and myelosuppression than other patients.	didanosine	249-259	CD4 molecule	Homo sapiens	60-63
7840911-7	1994	There was a correlation between the plasma didanosine concentration and an improvement in IQ (Intelligence Quotient) and p24 status.	didanosine	43-53	transmembrane p24 trafficking protein 2	Homo sapiens	121-124
7840911-9	1994	The combination of various doses of didanosine with zidovudine was associated with a reduction in viral titer, a significant increase in CD4 cell counts and a trend towards increased weight in many children.	didanosine	36-46	CD4 molecule	Homo sapiens	137-140
8089546-4	1994	Culture of 2 isolates from two patients treated with AZT more than 6 months before switched to ddI therapy showed CPE in the presence of AZT and HIV-1 p24 antigen was detected by ELISA in the supernatants.	didanosine	95-98	transmembrane p24 trafficking protein 2	Homo sapiens	151-154
7803875-2	1994	CASE SUMMARY: In June 1992 didanosine 200 mg po bid was initiated in a 30-year-old man with AIDS.	didanosine	27-37	BH3 interacting domain death agonist	Homo sapiens	48-51
7765215-1	1994	Data are presented which indicate that combinations of rCD4 immunoglobulin with azidothymidine, dideoxyinosine or 0.5 beta mouse monoclonal antibodies directed against the V3 region of HIV-1, were more effective in treatment of acute HIV infection in vitro than each compound alone.	didanosine	96-110	Cd4 molecule	Rattus norvegicus	55-59
7526781-9	1994	These data indicate differential antiviral activities of ddI and AZT in the different cells with the following rank order of drug sensitivity: MOLT4 > HT1080 > U937.	didanosine	57-60	cell division cycle 123	Homo sapiens	154-160
8089546-5	1994	Culture of 6 of 7 isolates from three patients treated with ddI after long-term therapy with AZT also showed CPE in the presence of 1.0 microM AZT and HIV-1 p24 antigen was detected.	didanosine	60-63	transmembrane p24 trafficking protein 2	Homo sapiens	157-160
8045675-6	1994	We report here the results of studies designed to evaluate the effect of interleukin-3 (IL-3) on its ability to influence the hematopoietic toxicity associated with zidovudine and ddI following combination with retroviral-infected murine bone marrow cells.	didanosine	180-183	interleukin 3	Mus musculus	73-86
8067781-0	1994	Effect of 3"-azido-3"-deoxythymidine and 2",3"-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.	didanosine	41-61	CD8a molecule	Homo sapiens	140-143
8067781-2	1994	We studied the ability of 3"-azido-3"-deoxythymidine (AZT) and 2",3"-dideoxyinosine (ddI) to inhibit the establishment of HIV-1 infection in CD8+ cells that were derived from cultures of peripheral blood lymphocytes exposed to both virus and drug.	didanosine	63-83	CD8a molecule	Homo sapiens	141-144
8067781-2	1994	We studied the ability of 3"-azido-3"-deoxythymidine (AZT) and 2",3"-dideoxyinosine (ddI) to inhibit the establishment of HIV-1 infection in CD8+ cells that were derived from cultures of peripheral blood lymphocytes exposed to both virus and drug.	didanosine	85-88	CD8a molecule	Homo sapiens	141-144
8067781-5	1994	We also performed a time course experiment to determine whether HIV-1 infection of CD8+ cells would be affected by treatment of peripheral blood lymphocytes with AZT or ddI for different intervals following exposure to virus.	didanosine	169-172	CD8a molecule	Homo sapiens	83-86
8031060-2	1994	These mutants (AIR-1 and AIR-3) displayed a 13-fold resistance to AZT but had less than a 2-fold decrease in susceptibility to ddI.	didanosine	127-130	zinc finger CCHC-type containing 7	Homo sapiens	15-20
8045675-6	1994	We report here the results of studies designed to evaluate the effect of interleukin-3 (IL-3) on its ability to influence the hematopoietic toxicity associated with zidovudine and ddI following combination with retroviral-infected murine bone marrow cells.	didanosine	180-183	interleukin 3	Mus musculus	88-92
8045675-8	1994	Dose-escalation IL-3 provided protection of anti-viral drug induced suppression of progenitor cells when combined in the presence of the ID50 concentration of either zidovudine or ddI; however, when zidovudine and ddI were combined, IL-3 was less effective in providing protection against drug-induced toxicity at any concentration examined.	didanosine	180-183	interleukin 3	Mus musculus	16-20
8045675-8	1994	Dose-escalation IL-3 provided protection of anti-viral drug induced suppression of progenitor cells when combined in the presence of the ID50 concentration of either zidovudine or ddI; however, when zidovudine and ddI were combined, IL-3 was less effective in providing protection against drug-induced toxicity at any concentration examined.	didanosine	214-217	interleukin 3	Mus musculus	16-20
8515096-1	1993	To determine the incidence of B19 infection in patients with AIDS who were being treated with dideoxyinosine, serial sera (n = 28) taken over a 2-year period from 14 individuals were analyzed with respect to anti-B19 serology and the presence of B19 DNA.	didanosine	94-108	eva-1 homolog C	Homo sapiens	30-33
7905722-11	1994	CONCLUSIONS: This study shows a positive treatment effect for switching from zidovudine to didanosine among patients with either AIDS-related complex or AIDS and validates the common practice of using clinical signs or a decrease in the CD4 count as an indication for changing therapy.	didanosine	91-101	CD4 molecule	Homo sapiens	237-240
8379600-13	1993	CONCLUSIONS: Combination therapy with zidovudine and didanosine produced larger and more sustained increases in CD4+ cell counts, more frequent decreases in plasma HIV-1 RNA titers, and more stable hematologic status than zidovudine therapy alone.	didanosine	53-63	CD4 molecule	Homo sapiens	112-115
1350471-10	1992	Phase I studies indicate that ddI has a beneficial effect on the CD4+ cell counts and HIV p24 antigen concentrations.	didanosine	30-33	transmembrane p24 trafficking protein 2	Homo sapiens	90-93
8425018-3	1993	Didanosine therapy was associated with a significant increase in CD4 counts and a prolonged decrease in serum levels of p24 antigen relative to baseline.	didanosine	0-10	CD4 molecule	Homo sapiens	65-68
8425018-3	1993	Didanosine therapy was associated with a significant increase in CD4 counts and a prolonged decrease in serum levels of p24 antigen relative to baseline.	didanosine	0-10	transmembrane p24 trafficking protein 2	Homo sapiens	120-123
8426301-1	1993	Didanosine (ddI) is a purine analogue that demonstrates in vitro anti-human immunodeficiency virus (HIV) activity, effects on the surrogate markers CD4+ T-lymphocytes and p24 antigen, and has adequate oral bio-availability.	didanosine	0-10	transmembrane p24 trafficking protein 2	Homo sapiens	171-174
8426301-1	1993	Didanosine (ddI) is a purine analogue that demonstrates in vitro anti-human immunodeficiency virus (HIV) activity, effects on the surrogate markers CD4+ T-lymphocytes and p24 antigen, and has adequate oral bio-availability.	didanosine	12-15	transmembrane p24 trafficking protein 2	Homo sapiens	171-174
1379914-5	1992	Didanosine also improved CD4+ cell counts in a phase II/III trial in patients previously treated with zidovudine, whereas cell counts declined in patients continuing zidovudine therapy.	didanosine	0-10	CD4 molecule	Homo sapiens	25-28
8093845-1	1993	The relation between the average steady-state plasma concentration (Cpss) of didanosine and selected measures of efficacy, such as CD4 cell count, p24 antigenemia, and weight gain, was evaluated in patients participating in a phase 1 safety and pharmacokinetics study.	didanosine	77-87	CD4 molecule	Homo sapiens	131-134
8468123-7	1993	We report here the results of studies comparing the toxicity profile of zidovudine versus ddI on their ability to influence several classes of hematopoietic progenitor stem cells, e.g. granulocyte--macrophage (CFU-GM), megakaryocyte (CFU-Meg) and erythroid (CFU-E/BFU-E) following in vitro co-culture with normal human bone marrow.	didanosine	90-93	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	238-241
1347442-0	1992	Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection.	didanosine	21-35	transmembrane p24 trafficking protein 2	Homo sapiens	62-65
1347442-2	1992	OBJECTIVE: To determine the relation between exposure to dideoxyinosine (ddl) and increased CD4 cell counts and suppression of serum p24 antigen in patients infected with the human immunodeficiency virus (HIV).	didanosine	57-71	CD4 molecule	Homo sapiens	92-95
1347442-2	1992	OBJECTIVE: To determine the relation between exposure to dideoxyinosine (ddl) and increased CD4 cell counts and suppression of serum p24 antigen in patients infected with the human immunodeficiency virus (HIV).	didanosine	57-71	transmembrane p24 trafficking protein 2	Homo sapiens	133-136
1727902-4	1992	A plasma ddI concentration-response relationship was observed for both decline in viral p24 antigen levels and improvement in intelligence quotient score.	didanosine	9-12	transmembrane p24 trafficking protein 2	Homo sapiens	88-91
1576055-5	1992	In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase.	didanosine	54-57	purine nucleoside phosphorylase	Homo sapiens	97-128
1576055-5	1992	In addition to the intracellular formation of ddA-TP, ddI can be broken down to hypoxanthine, by purine nucleoside phosphorylase (PNP) and to uric acid, by xanthine oxidase.	didanosine	54-57	purine nucleoside phosphorylase	Homo sapiens	130-133
1540653-0	1992	Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2",3"-dideoxyadenosine and 2",3"-dideoxyinosine.	didanosine	130-150	adenylosuccinate lyase	Homo sapiens	31-53
1677450-3	1991	In the present in vitro study, the formation in human T cells (MOLT-4, ATH8, and CCRF-CEM) of the pharmacologically active metabolite of ddIno and ddAdo, 2",3"-dideoxyadenosine-5"-triphosphate (ddATP), was found to be stimulated 2-4-fold by appropriate concentrations of inosinate dehydrogenase (IMPD) inhibitors such as ribavirin, tiazofurin, and mycophenolic acid.	didanosine	137-142	inosine monophosphate dehydrogenase 1	Homo sapiens	296-300
1677450-5	1991	No change was noted in the intracellular concentration of the corresponding physiological deoxynucleoside-5"-triphosphate, dATP; positive correlation was observed, however, between the increase in ddATP formation from ddIno and the increase in intracellular IMP occurring as a consequence of IMPD inhibition.	didanosine	218-223	inosine monophosphate dehydrogenase 1	Homo sapiens	292-296
1677450-6	1991	The results support the hypothesis that the stimulation of ddATP formation seen when ddIno is combined with ribavirin or other IMPD inhibitors is a consequence of an increased concentration of IMP, the major phosphate donor for the initial phosphorylation step in the anabolism of ddIno to ddATP, i.e., ddIno----ddIMP.	didanosine	281-286	inosine monophosphate dehydrogenase 1	Homo sapiens	127-131
1974727-6	1990	In patients treated with ddI, the mean number of CD4+ lymphocytes increased from 124/mm3 at baseline to 199/mm3 at 24 weeks (P = .0027) and the mean leukocyte count, total lymphocyte count, and hemoglobin level showed increases (all P less than .01) after 12 weeks.	didanosine	25-28	CD4 molecule	Homo sapiens	49-52
2033586-8	1991	All 2-amino-6-halo-ddPs and 6-halo-ddPs were substrates for adenosine deaminase (ADA) and were converted to ddG or ddI, respectively.	didanosine	115-118	adenosine deaminase	Homo sapiens	81-84
2223241-6	1990	However, it had varying effects on different dideoxynucleosides: GM-CSF increased the net anti-HIV activity of 3"-azido2",3"-dideoxythymidine (AZT), while at the same time it reduced the activity of 2",3"-dideoxycytidine (ddC) and 2",3"-dideoxyinosine (ddI).	didanosine	231-251	colony stimulating factor 2	Homo sapiens	65-71
2223241-6	1990	However, it had varying effects on different dideoxynucleosides: GM-CSF increased the net anti-HIV activity of 3"-azido2",3"-dideoxythymidine (AZT), while at the same time it reduced the activity of 2",3"-dideoxycytidine (ddC) and 2",3"-dideoxyinosine (ddI).	didanosine	253-256	colony stimulating factor 2	Homo sapiens	65-71
34791318-3	2022	As many ARVs are substrates and/or inhibitors or inducers of CYP3A4, there is concern about DDIs with dexamethasone either as a perpetrator or a victim.	didanosine	92-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	61-67
33940027-9	2021	In summary, Tiny-TIM is a very reliable and promising GI model to successfully predict the nature of DDI when ARAs are co-administered with the drug of interest.	didanosine	101-104	Rho guanine nucleotide exchange factor 5	Homo sapiens	17-20
2139173-9	1990	The administration of ddI was associated with statistically significant decreases in serum level of p24 antigen and increases in the numbers of CD4 cells at 2, 6, 10, and 20 weeks.	didanosine	22-25	transmembrane p24 trafficking protein 2	Homo sapiens	100-103
2139174-9	1990	Treatment with ddI was associated with an increase in the mean number of CD4 lymphocytes from 125 per cubic millimeter at base line to 182 per cubic millimeter after 10 weeks (P = 0.005).	didanosine	15-18	CD4 molecule	Homo sapiens	73-76
35486324-2	2022	Ritonavir is a strong inhibitor for CYP3A4/5-mediated DDIs and has been proposed as a suitable alternative to ketoconazole.	didanosine	54-58	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-44